Health Care [ 9/12 ] | Biotechnology [ 43/74 ]
NASDAQ | Common Stock
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases.
It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer.
It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab.
Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 4, 25 | -0.12 Increased by +80.00% | -0.13 Increased by +7.69% |
| Aug 7, 25 | -0.10 Decreased by -150.00% | -0.13 Increased by +23.08% |
| Jun 13, 25 | -0.14 Decreased by -14.83% | -0.12 Decreased by -14.83% |
| Mar 17, 25 | -0.14 Decreased by -2.07% | -0.12 Decreased by -19.08% |
| Nov 5, 24 | -0.60 Decreased by -400.00% | -0.11 Decreased by -445.45% |
| Aug 6, 24 | -0.04 Increased by +71.43% | -0.11 Increased by +63.64% |
| May 6, 24 | -0.12 Increased by +29.41% | -0.13 Increased by +7.69% |
| Mar 19, 24 | -0.14 Increased by +33.33% | -0.12 Decreased by -16.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -10.16 M Increased by +74.74% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -8.00 M Decreased by -87.66% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | 15.19 M Increased by +366.50% | Increased by +N/A% Decreased by N/A% |
| Dec 31, 24 | 88.00 K Decreased by -64.23% | -12.11 M Decreased by -82.07% | Decreased by -13.76 K% Decreased by -408.96% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -40.22 M Decreased by -570.28% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -4.26 M Increased by +34.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -5.70 M Increased by +27.59% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 246.00 K Increased by +N/A% | -6.65 M Increased by +32.22% | Decreased by -2.70 K% Decreased by N/A% |